Oclacitinib 10 years later: lessons learned and directions for the future

Rosanna Marsella University of Florida, Gainesville, FL

Search for other papers by Rosanna Marsella in
Current site
Google Scholar
PubMed
Close
 DVM, DACVD
,
Katherine Doerr Maitland, FL

Search for other papers by Katherine Doerr in
Current site
Google Scholar
PubMed
Close
 DVM, DACVD
,
Andrea Gonzales Zoetis Global Therapeutics Research, Kalamazoo, MI

Search for other papers by Andrea Gonzales in
Current site
Google Scholar
PubMed
Close
 PhD
,
Wayne Rosenkrantz Animal Dermatology Clinic, Tustin, CA

Search for other papers by Wayne Rosenkrantz in
Current site
Google Scholar
PubMed
Close
 DVM, DACVD
,
Jennifer Schissler Zoetis Petcare Veterinary Professional Services, Parsippany, NJ

Search for other papers by Jennifer Schissler in
Current site
Google Scholar
PubMed
Close
 DVM, DACVD
, and
Amelia White Auburn University College of Veterinary Medicine and Clinical Sciences, Auburn, AL

Search for other papers by Amelia White in
Current site
Google Scholar
PubMed
Close
 DVM, DACVD

Abstract

Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. Many studies and case reports have been published in the past 10 years on the efficacy and safety of this medication, both at labeled doses to treat allergic dogs and off label to treat other diseases and given to other species. Concerns and confusion have occurred for both clinicians and owners regarding the long-term safety of this drug. The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and clinical safety of oclacitinib, based on evidence and published literature. We also aim to summarize the lessons learned in the past 10 years and to propose directions for the future.

Abstract

Oclacitinib was approved in the United States 10 years ago for the management of atopic dermatitis (AD) and allergic skin disease in dogs. Many studies and case reports have been published in the past 10 years on the efficacy and safety of this medication, both at labeled doses to treat allergic dogs and off label to treat other diseases and given to other species. Concerns and confusion have occurred for both clinicians and owners regarding the long-term safety of this drug. The purpose of this review is to present the current knowledge on the efficacy, speed of action, effects on the immune system, and clinical safety of oclacitinib, based on evidence and published literature. We also aim to summarize the lessons learned in the past 10 years and to propose directions for the future.

All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 22494 13749 1285
PDF Downloads 23024 13695 1357
Advertisement